Videos

The study sought to determine the impact of a rurally focused telemedicine program on patient outcomes.

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

The leukemia expert discussed exciting research being presented at this year’s ASH Annual Meeting.

The kidney cancer expert from the National Cancer Institute spoke about what ongoing research in the field of kidney cancer is most encouraging and where research should continue to be focused.

The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill Cornell Medicine spoke about exciting research coming out of ASH for patients with chronic lymphocytic leukemia.

Voorhees noted that despite challenges associated with the COVID-19 pandemic, emerging therapies offer hope for patients with multiple myeloma.

Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

The director of the new Women’s Lung Cancer Program at Mount Sinai spoke about the gaps in lung cancer research for women and what she hopes this new program will offer women moving forward.

Given that smoking is one of the major risk factors for recurrence of any cancer, Tsao explained that it's crucial that providers focus on smoking cessation in patients with cancer.

Given that diagnosing lung cancer in its early stages can lead to successfully eliminating lung cancer with surgery alone, the importance of closing this disparity gap is critical.

The SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team have developed laboratory models to understand the inflammatory process in the lung’s bronchial cells, and how that relates to early lung cancer development.

Ahlstrom explained the necessity of offering patients with cancer telehealth opportunities and what patients with cancer will lose should telehealth waivers expire.

Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.

Jeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.

Research published by Galvin, et al. in the journal ONCOLOGY® demonstrated the necessity to understand why eligible patients with pancreatic adenocarcinoma elect not to participate in early-phase clinical trials.

Data from the COMBI-AD Trial evaluating dabrafenib and trametinib to treat melanoma was analyzed by Hussein Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center.

CancerNetwork spoke with Jason Luke, MD, FACP, at the SMR Conference regarding the latest updates on melanoma.

The Cancer Experience Registry was developed by the Cancer Support Community in order to collect information about the emotional and social effects of living with a cancer diagnosis.

Jeffrey Schneider, MD, and Marc Braunstein, MD, PhD, spoke about their recent article published in the journal ONCOLOGY® regarding the management of patients with cancer during the COVID-19 pandemic.

The leukemia expert spoke about the importance of genetic testing for patients with acute myeloid leukemia and other important considerations for this patient population throughout the pandemic.

Venetoclax was granted approval in combination with azacitidine, decitabine, or low dose cytarabine earlier this month for adults 75 years or older with newly diagnosed acute myeloid leukemia or those who have comorbidities precluding intensive induction chemotherapy.

The expert in breast imaging spoke about the latest in breast imaging and the new technologies that are helping to advance the field.

The expert in breast imaging spoke about the use of the technology, and why it is more effective than traditional mammograms.

New research from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, given that a sufficiently large pool of agents is provided.

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

New research reported that guidelines to reduce the number of opioids prescribed to patients following surgery may be missing a small group of patients that need a greater level of pain control.

Among accredited US cancer centers, hospitals which serve primarily minority patients were found to be as likely as other hospitals to offer the standard of surgical care for early-stage breast cancer.

Research suggested that limited English-language proficiency is a risk factor for getting potentially lifesaving screening mammograms less often.